Makes perfect sense to do a cap raise incase something unexpected happens in one of the trials. Given what we know, if one of the trials is not successful it wont be because Bisantrene doesn't work IMO. This means we'll be able to use whatever data we get and design a better more targeted trial, however, the SP would fall off a cliff in this instance. Imagine having to raise then? Given our 500M market cap, I hope they dilute us by around 5% and raise 25M as a contingency.
Ann: Trading Halt, page-25
-
- There are more pages in this discussion • 344 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
